AstraZeneca, Daiichi Sankyo announce Enhertu plus pertuzumab demonstrated clinically meaningful improvement as 1st-line therapy for patients with metastatic breast cancer

DESTINY-Breast09 Phase III trial of AstraZeneca and Daiichi Sankyo’s Enhertu is the first trial in more than a decade to demonstrate superior efficacy across a broad HER2-positive metastatic patient population versus current 1st-line standard of care

Shin-Etsu Chemical and Hokkaido University develop lipid nanoparticle production system capable of both small-batch, high-mix production

Novartis to invest $23 billion on expansion of manufacturing and R&D facilities in US

Expanded US manufacturing and R&D presence with investment in 10 facilities, including 7 brand new facilities

Plex Research partners With Ginkgo Bioworks on AI powered drug discovery to identify novel disease mechanisms

Findings likely to generate hypotheses about potential new uses of drugs

Mankind unveils HealthOK’s 100% vegetarian multivitamin tablets campaign with Archana Puran Singh

Merck seeks FDA approval for subcutaneous pembrolizumab

Subcutaneous pembrolizumab administered every six weeks with a median injection time of two minutes, in combination with chemotherapy, shows consistent results across reported efficacy and safety endpoints compared to IV KEYTRUDA in combination with chemotherapy

CKD cases surge to 16.38% in Indians aged 15+

Experts urge early detection & better access to care

Glenmark Nutrition Awards 2025 celebrates innovation and impact in fight against malnutrition

403 entries from 22 states covering 168 districts highlight groundbreaking initiatives vital to improving national nutrition metrics.

India’s CRDMO sector growth potential at $22 - $25 Billion by 2035: BCG-IPSO Report

Eleven CRDMOs collaborate to form IPSO with the aim to elevate India’s position in the global pharmaceutical value-chain

FDA grants EUA to Aptitude’s Covid/flu multiplex test for OTC use